Featured Story | By Nick Paul Taylor The unstoppable march of Eli Lilly’s tirzepatide continues. Having previously shown the dual GIP/GLP-1 agonist reduces the weight of people with diabetes, Lilly has now delivered a hit in its first phase 3 pure play obesity trial, putting Novo Nordisk’s Wegovy on notice that a serious challenger may be on the horizon. read more |
| |
|---|
|
|  | Harness the power of eCOA in your next trial Keep patients at the center of care while increasing efficiencies, data integrity and regulatory compliance. IQVIA’s leaders will help you deploy strategic eCOA tools, maximize patient needs and acquire real-time insights that demonstrate results. Learn more. |
Top Stories By Annalee Armstrong Pfizer is getting back to work on a late-stage test for its Duchenne muscular dystrophy gene therapy. The decision comes several months after a patient death in a phase 1 trial drew a clinical hold on the medicine from the FDA. read more By Max Bayer Sio Gene Therapies is now without a product after ending clinical development of its last two assets, prompting the company to seek an emergency exit and warn of impending layoffs. read more Sponsored By: QIAGEN Digital Insights Biomedical knowledge graphs can power many different application in drug discovery. Learn which key feature you should look for and why. read more By Gabrielle Masson Riding high after an Amgen partnership and a $102 million funding round so far this year, Plexium shows no signs of slowing down. Instead, it's inked a new agreement with AbbVie focused on neurological conditions. read more By Nick Paul Taylor GV, Northpond Ventures and Sanofi Ventures have joined forces to pump $100 million into OMass Therapeutics, teeing the British biotech up to advance candidates against hard-to-hit targets toward the clinic. read more By Max Bayer New research from an international team of scientists found that a specific kind of lipid associated with winding down the inflammation could be a boost in treating multiple sclerosis. A new study found administering the lipid reduced pro-inflammatory proteins and immune cells. read more By Fraiser Kansteiner BioMarin tallied record quarterly revenues of $519 million in the first three months of 2022, with new achondroplasia med Voxzogo chipping in $20 million. read more By Zoey Becker When Amgen released first-quarter results on Wednesday, its sales and profit numbers were again overshadowed by a bombshell tax disclosure. read more By Angus Liu Five years after its first FDA approval in eczema, Sanofi's Dupixent is still blazing a trail in inflammatory diseases. That's the evaluation of Sanofi's global head of specialty care after the drug's sales shot up 46% in the first quarter of 2022. read more Resources Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Presented By: Springer Nature The journey of drug development in 2021 delivered to your inbox: top 10 AdisInsight drug profiles viewed, new drug profiles released, overview of drug launches, key deals, research trends in 2021 and much more (free of charge). Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market. Sponsored by: Thermo Fisher Scientific Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific. Cancer Progress 2022: Hear from Leading Oncology Innovators May 10-12, 2022 | Virtual Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 24, 2022 | Free Virtual Event Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next Gen June 29-30, 2022 | Free Virtual Event Fierce Pharma PR & Communications Summit East July 19-20, 2022 | Jersey City, NJ Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 
